Cumberland Pharmaceuticals (CPIX) Reports Q3 EPS of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cumberland Pharmaceuticals Reports Third Quarter & Year To Date 2015 Financial Results
November 3, 2015 4:05 PM ESTNASHVILLE, Tenn., Nov. 3, 2015 /PRNewswire/ --Â Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2015 financial results with Net Revenues of $7.9 million and Adjusted Earnings of $0.7 million or $0.04 per share. Net Revenues for the first nine months of 2015 were $25.5 million with Adjusted Earnings of $3.8 million or $0.22 per share.
As of September 30, 2015 the Company had approximately $92 million in total assets including approximately $53 million in cash and investments. Total Liabilities were $14.5 million... More
